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With cases of severe acute respiratory syndrome
(SARS) occurring across geographic regions, data collec-
tion on the effectiveness of intervention strategies should
be standardized to facilitate analysis. We propose a mini-
mum dataset to capture data needed to examine the basic
reproduction rate, case status and criteria, symptoms, and
outcomes of SARS. 
F
irst detected in China, confirmed and probable cases of
severe acute respiratory syndrome (SARS) have now
appeared in at least 30 countries in five continents. SARS
is the first new severe infectious disease to occur in the
21st century, and little is known about its epidemiologic
features (1). To assess the effect of SARS on public health
and outcomes, data are needed about who becomes ill, how
they contracted their illness, and the sequelae.
A minimum set of data on intervention effectiveness
should be collected in a uniform manner from each identi-
fied SARS case-patient at each location. Without such
standardization, datasets from different locales may not be
sufficiently comparable, thereby limiting the ability to sci-
entifically evaluate both the effect of SARS and the inter-
ventions to control and prevent its spread. 
We propose a minimum set of epidemiologic and clini-
cal variables that should be among the top priorities when
designing data collection protocols related to SARS inter-
ventions. We set priorities for the variables in the minimum
dataset as a guide for agencies unable to collect all the rec-
ommended data. Additionally, we summarize the health
measures constructed from each of the variables, along with
the possible policy implications, to provide further guidance
to health agencies regarding the importance of each vari-
able. A case study is available in an online appendix. 
Previous tools have been used to understand the spread
of SARS and associated illnesses (2). These tools have not
provided all necessary data to facilitate modeling useful-
ness and cost-effectiveness of interventions. Researchers
have published results from relevant epidemiologic data,
but no forms of itemized data are readily available (3). Our
minimum dataset differs from minimum reporting require-
ments recently published by the World Health
Organization (WHO) (2). WHO data templates include a
daily summary of SARS cases to be reported at the nation-
al level and a case-reporting form that contains detailed
clinical information (based on current WHO case defini-
tions), including patient demographics, exposure, contact
follow-up, daily reporting of symptoms, hospital admis-
sion, final case classification, and final case status. The
dataset we propose captures information on length of
exposure, incubation period from exposure to symptom
onset, and use of health care resources (e.g., length of hos-
pitalization, length of isolation, and admission to intensive
care) not currently collected by WHO’s template.
Proposed Minimum Dataset 
and Data Prioritization
Figures 1 and 2 (a downloadable document is available
online at http://www.cdc.gov/ncidod/eid/vol10no7/03-
0749-G1.htm and http://www.cdc.gov/ncidod/eid/vol10
no7/03-0749-G2.htm) illustrate the minimum epidemiolog-
ic variables needed to evaluate the public health effect of
SARS and the cost of interventions. These data would pro-
vide the evidence to determine key epidemiologic relation-
ships, including the incubation period (time from exposure
to onset of symptoms), the onset of symptoms leading to
hospitalization, and the outcomes resulting from treatment
(either discharge of patient or death). Descriptions of the
variables listed in Figures 1 and 2, along with suggestions
for coding, are provided in the online Appendix 1
(http://www.cdc.gov/ncidod/eid/vol10no7/03-0749_
app1.htm). For all tables, the column heading corresponds
with the variable name (e.g., A represents the case identifi-
cation [ID] number, B represents sex, C represents age).
Figure 1 captures case-patient demographics, expo-
sures, and symptoms. Suggested coding for demographic
variables (online Appendix 1) include patient ID and age
as continuous variables and sex and coexisting conditions
(e.g., cardiovascular disease, diabetes) or syndromes
(HIV/AIDS) as categorical variables. Other categories for
coexisting conditions can be added as appropriate (e.g.,
smoking). An important distinction should be made
between patients who have no known diagnosed coexist-
ing conditions (coded as none known) as opposed to
patients for whom information about coexisting conditions
is not available or missing (coded as unknown). 
In Figure 1, exposure variables and their suggested cod-
ing include date (DD/MM/YY), source (whether the
source is already identified and included in the data table
as an observed patient with an assigned ID or whether the
source is unknown), duration of exposure (<30 minutes,
30–59 minutes, or >60 minutes), and locale (whether expo-
sure occurred at home, in a hospital, or some other loca-
tion). The same variables are measured for each exposure,
and the table can be expanded to collect information on all
known exposures. 
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respiratory. For each symptom, onset date and type (a cat-
egorical variable that can be expanded for patients with
multiple symptoms) are collected. Suggested categories
for symptoms include fever, myalgia, dyspnea, headache,
chills, diarrhea, nausea, sore throat, arthralgia, chest pain,
productive cough, nonheadache neurologic symptoms
(e.g., dizziness), rhinorrhea or runny nose, vomiting, and
abdominal pain. The list of symptom categories can be
revised or extended as needed.
Figure 2 contains information on case criteria, along
with health outcomes associated with the case. Categorical
variables making up case status include the clinical case
criteria (either asymptomatic or mild respiratory illness,
moderate illness, severe respiratory illness, or none), epi-
demiologic criteria (travel within 10 days to infected area,
close contact, both, or none), laboratory confirmation (yes,
no, or undetermined), and case classification (probable,
suspected, or noncase). 
Outcome variables include hospitalization (along with
admission date if hospitalized), treatment status (antiviral
agent, antibacterial agent, or other treatment), isolation
start date, number of days isolated (a continuous vari-
able), number of days on ventilation or in intensive care
(continuous variables), discharge date (0 if still hospital-
ized), death (yes or no), and date of death. The online
Appendix 2 (available at http://www.cdc.gov/ncidod/eid/
vol10no7/03-0749_app2.htm) provides an example of
Figures 1 and 2 filled out with data from four “typical”
case-patients. The variable categories from the tables in
online Appendix 1 can be readily extended or revised as
new information about SARS becomes available. The
footnotes offer the definitions that served as the basis for
the suggested categories. 
Priority Classification Groups
Online Appendix 1 also provides proposed priority
classification groups for each variable listed in Figures 1
and 2. Variables that are labeled “priority group 1” repre-
sent the most important set of variables, and those labeled
as “priority group 3,” the least important. The table in
online Appendix 1 provides a summary of how each vari-
able contributes to important health policy questions relat-
ed to the SARS outbreak. Taken together, these tables can
provide guidance to health organizations regarding which
data should be collected so that the needed policy analysis
can be conducted (Table).
Priority group 1 variables (sex, age, date and source of
exposure, date of symptom onset, and case status and cri-
teria variables) contain the information on the transmission
rate of the disease and incubation periods. These variables
provide crucial information in determining the basic repro-
duction number of an infection (defined as the expected
number of secondary infectious cases resulting from one
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Figure 1. Schematic of table illustrating the epidemiologic data needed to evaluate impact of SARS and interventions: data relating to
exposures and date of onset of symptoms. Data entry columns allow for multiple exposures and can expand as needed. Suggestions for
coding the data for this table are given in Appendix Table 1 in online Appendix 1. A downloadable version of this table is available online
(http://www.cdc.gov/ncidod/eid/vol10no7/03-0749-G1.htm).
Figure 2. Schematic of table illustrating the epidemiologic data needed to evaluate impact of SARS and interventions: data relating to
case status and outcomes. Suggestions for coding the data for this table are given in Appendix Table 2 in online Appendix 1. Data entry
columns move according to footnotes in Appendix Table 2 (letters at top of each column are used in describing data and rationale for
each data point). A downloadable version of this table is available online (http://www.cdc.gov/ncidod/eid/vol10no7/03-0749-G2.htm). primary case in a susceptible population) (4,5). This meas-
ure is vital for estimating the impact of control measures to
reduce the transmission of SARS (4,5). Priority group 2
variables (duration and locale of exposure; hospitalization,
including start date; isolation, including start date; and
death, including date of death) provide information that
can be used to evaluate the risk for hospitalization or death
associated with exposure, length of incubation, and impact
of isolation. Priority group 3 variables (coexisting condi-
tions; categories of symptoms; treatment status; ventilation
or intensive care, including start date; and date of dis-
charge) are not essential information for containing SARS
outbreaks but provide additional information about health-
care resources (treatment and intensive care) used to treat
SARS patients. Priority group 3 variables can also be used
by hospital administrators and public health officials to
plan and prepare for a sudden change in resource use dur-
ing a catastrophic infectious disease outbreak (e.g., pan-
demic influenza) (6).
Conclusions
The emergence of a novel disease like SARS, which
requires a global public health response to contain its
spread, has illustrated the need for collecting effectiveness
data in a uniform manner. Given the potential for a large
variation in location-specific circumstances, producing a
single questionnaire that would be entirely suitable for all
locales would be difficult. Figures 1 and 2 illustrate some
of the most important data needed to understand and con-
trol the disease. The tables present a standardized protocol
and approach for ensuring that all the proposed data have
been collected. As an illustration of the use of the tables, a
case study is presented in online Appendix 2. Identifying
effective interventions during an outbreak becomes impor-
tant in managing public health resources. The minimum
dataset proposed here provides a basis for standardizing
the collection of data from various geographic locations,
thereby facilitating the analysis of SARS interventions.
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Table. Potential calculations and policy implications from collected data 
Variables
a   What could be calculated  Policy implications 
E, I, M, and Q  Incubation period(s)   How soon should an exposed person be identified and 
placed in quarantine 
A, B, C, F, J, and N  Who infected whom  Monitoring of disease spread and impact of interventions 
E, I, M, G, K, O, Q, H, L, 
and P 
When and where an infectious person infects 
another and duration of disease 
Evaluation of infectiousness at different stages of disease 
and development or refinement of recommendations for 
persons exposed to SARS 
D, E, I, M, G, K, O, H, L, P 
W, X, and AF 
Effect of preexisting medical conditions on 
risk for hospitalization and death 
Evaluation of medical response, with initial medical 
contact and treatment based on patients’ risk factors 
D, E, I, M, G, K, O, H, L, P, 
W, X, Y, Z, AA, AB, AC, AD, 
AE, and AF 
Effect of certain preexisting conditions,  
type of contact, and length of incubation on 
increased risk for hospital isolation, 
ventilation, and intensive care 
Evaluation of medical response, with analyses of how 
patients’ risk factors impact allocation of hospital-based 
resources 
R, S, T, U, V, and W  Classification of possible SARS cases   Evaluation of medical response, with degree of certainty 
of SARS diagnosis impacting allocation of health care 
resources 
E, I, M, F, J, N, H, L, P, Q, 
W, Z, and X 
Effect of isolation on spread of disease  Evaluation of interventions’ effect on slowing and 
deterring the spread of disease 
AG and AH  Death as an outcome   Evaluation of the severity of the outbreak 
aFrom data entry columns, Figures 1 and 2. 